Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Free Report) has been assigned a consensus recommendation of “Reduce” from the eight analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and seven have issued a hold rating on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $23.33.
Several brokerages have issued reports on AMPH. Wells Fargo & Company raised their price target on Amphastar Pharmaceuticals from $20.00 to $25.00 and gave the company an “equal weight” rating in a report on Friday, November 6th. Piper Sandler decreased their target price on Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “neutral” rating on the stock in a research report on Friday, August 7th. Weiss Ratings upgraded Amphastar Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, November 4th. Wall Street Zen raised Amphastar Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, November 9th. Finally, Barclays lifted their price target on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the stock an “equal weight” rating in a report on Tuesday, August 18th.
View Our Latest Research Report on AMPH
Amphastar Pharmaceuticals Stock Up 2.1%
NASDAQ:AMPH opened at $29.71 on Thursday. Amphastar Pharmaceuticals has a twelve month low of $16.65 and a twelve month high of $31.00. The firm has a market capitalization of $1.27 billion, a price-to-earnings ratio of 13.57, a price-to-earnings-growth ratio of 5.68 and a beta of 0.93. The company has a quick ratio of 2.36, a current ratio of 3.32 and a debt-to-equity ratio of 0.75. The stock’s 50 day moving average price is $26.33 and its two-hundred day moving average price is $22.44.
Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.86 by $0.28. Amphastar Pharmaceuticals had a net margin of 13.27% and a return on equity of 15.31%. The company had revenue of $207.61 million for the quarter, compared to analysts’ expectations of $197.52 million. Equities research analysts expect that Amphastar Pharmaceuticals will post 2.43 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, EVP Rong Zhou sold 10,000 shares of the stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $23.94, for a total transaction of $239,400.00. Following the transaction, the executive vice president owned 169,203 shares of the company’s stock, valued at $4,050,719.82. This represents a 5.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO William J. Peters sold 16,000 shares of the firm’s stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $28.03, for a total transaction of $448,480.00. Following the transaction, the chief financial officer directly owned 168,707 shares in the company, valued at $4,728,857.21. The trade was a 8.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 45,957 shares of company stock valued at $1,232,836 over the last quarter. 29.60% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Amphastar Pharmaceuticals
A number of institutional investors and hedge funds have recently modified their holdings of AMPH. Eurizon Capital SGR S.p.A. bought a new stake in shares of Amphastar Pharmaceuticals during the 3rd quarter valued at about $33,000. Nisa Investment Advisors LLC increased its holdings in shares of Amphastar Pharmaceuticals by 183.3% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,422 shares of the company’s stock worth $37,000 after buying an additional 920 shares during the last quarter. Quantbot Technologies LP purchased a new position in shares of Amphastar Pharmaceuticals during the second quarter worth approximately $39,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in Amphastar Pharmaceuticals in the 3rd quarter worth $56,000. Finally, State of Wyoming purchased a new position in Amphastar Pharmaceuticals in the 2nd quarter worth approximately $142,000. 65.09% of the stock is owned by hedge funds and other institutional investors.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals is a biopharmaceutical company that develops, manufactures and markets generic and proprietary medicines, with a focus on products that can be technically challenging to produce. Its offerings include injectable, inhalation and intranasal medicines, as well as insulin active pharmaceutical ingredients. The company’s products include treatments and emergency medicines such as enoxaparin, glucagon and epinephrine products. Amphastar also markets BAQSIMI, a nasal powder used to treat severe low blood sugar, and Primatene MIST, an over-the-counter asthma inhaler.
Read More
- Five stocks we like better than Amphastar Pharmaceuticals
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
